Lupus erythematosus is a complex autoimmune disease characterized by skin and/or systemic involvement. Among systemic disorders, half of the patients will experience non-specific digestive symptoms, usually due to drug medication or transitory infections. In rare cases, lupus enteritis can be observed, and its diagnosis may precede the disease and/or be associated with an inflammatory bowel disease (IBD). Among the underlying mechanisms explaining the digestive damages observed in systemic lupus erythematosus (SLE) and the intestinal barrier function (IBF), increased intestinal permeability, microbiota dysbiosis, and intestinal immune system dysregulations are described in numerous murine and human studies. New therapeutic approaches in addition to conventional treatments are evoked in order to better control the IBF disruption and maybe prevent the onset or worsening of the disease. Thus, the aims of this review are to present the alterations of the digestive tract in SLE patients and the link between SLE and IBD as well as how the different elements of the IBF could participate in SLE pathogenesis.
ZhouWWuHZhaoM, et al.New insights into the progression from cutaneous lupus to systemic lupus erythematosus. Expert Rev Clin Immunol2020; 16(8): 829–837.
2.
BernatskySBoivinJFJosephL, et al.Mortality in systemic lupus erythematosus. Arthritis Rheum2006; 54(8): 2550–2557.
3.
MöcockelTBastaFWeinmann-MenkeJ, et al.B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmunity Reviews, 20(2), 2021, 102736. doi: 10.1016/j.autrev.2020.102736
4.
ZhangJRoschkeVBakerKP, et al.Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol2001; 166(1): 6–10.
5.
TsokosGCLoMSReisPC, et al.New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol2016; 12(12): 716–730.
6.
ZhouHLiBLiJ, et al.Dysregulated T cell activation and aberrant cytokine expression profile in systemic lupus erythematosus. Mediators Inflamm2019; 2019: 1–11.
7.
BrewerBNKamenDL. Gastrointestinal and hepatic disease in systemic lupus erythematosus. Rheum Dis Clin N Am2018; 44(1): 165–175.
8.
EckburgPBBikEMBernsteinCN, et al.Diversity of the human intestinal microbial flora. Science2005; 308(5728): 1635–1638.
9.
van der HeeBWellsJM. Microbial regulation of host physiology by short-chain fatty acids. Trends Microbiol2021; 29(8): 700–712.
10.
McGuckinMALindénSKSuttonP, et al.Mucin dynamics and enteric pathogens. Nat Rev Microbiol2011; 9(4): 265–278.
11.
MörbeUMJørgensenPBFentonTM, et al.Human gut-associated lymphoid tissues (GALT); diversity, structure, and function. Mucosal Immunol2021; 14(4): 793–802.
12.
GullbergESoderholmJD. Peyer’s patches and M cells as potential sites of the inflammatory onset in crohn’s disease. Ann N Y Acad Sci2006; 1072(1): 218–232.
13.
HarrisonOJPowrieFM. Regulatory T cells and immune tolerance in the intestine. Cold Spring Harb Perspect Biol2013; 5(7): a018341.
14.
RibotJCLopesNSilva-SantosB. γδ T cells in tissue physiology and surveillance. Nat Rev Immunol2021; 21(4): 221–232.
15.
LourençoSVDe CarvalhoFRGBoggioP, et al.Lupus erythematosus: clinical and histopathological study of oral manifestations and immunohistochemical profile of the inflammatory infiltrate. J Cutan Pathol2007; 34(7): 558–564.
16.
JanssensPArnaudLGalicierL, et al.Lupus enteritis: from clinical findings to therapeutic management. Orphanet J Rare Dis2013; 8: 67.
17.
JuJHMinJKJungCK, et al.Lupus mesenteric vasculitis can cause acute abdominal pain in patients with SLE. Nat Rev Rheumatol2009; 5(5): 273–281.
18.
ShorDBADahanSComaneshterD, et al.Does inflammatory bowel disease coexist with systemic lupus erythematosus?Autoimmun Rev2016; 15(11): 1034–1037.
19.
KatsanosKHVoulgariPVTsianosEV. Inflammatory bowel disease and lupus: a systematic review of the literature. J Crohns Colitis2012; 6(7): 735–742.
20.
ToulemondePAlricLValléeF, et al.Association entre un lupus érythémateux disséminé et une maladie de Crohn. Rev Médecine Interne2001; 22(4): 385–388.
21.
AzzouzDOmarbekovaAHeguyA, et al.Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. Ann Rheum Dis2019; 78(7): 947–956.
22.
DahanSShorDBAComaneshterD, et al.All disease begins in the gut: celiac disease co-existence with SLE. Autoimmun Rev2016; 15(8): 848–853.
23.
SoltaniZBaghdadiANejadhosseinianM, et al.Celiac disease in patients with systemic lupus erythematosus. Reumatologia2021; 59(2): 85–89.
24.
FreemanHJ. Adult celiac disease followed by onset of systemic lupus erythematosus. J Clin Gastroenterol2008; 42(3): 252.
25.
KimJWKwokSKChoeJY, et al.Recent advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus. Int J Mol Sci2019; 20(19): 4871.
26.
LeeMChangEB. Inflammatory bowel diseases (IBD) and the microbiome—searching the crime scene for clues. Gastroenterology2021; 160(2): 524–537.
27.
ZhangHLiaoXSparksJB, et al.Dynamics of gut microbiota in autoimmune lupus. Schloss PD. Appl Environ Microbiol2014; 80(24): 7551–7560.
28.
MaLMorelL. Loss of gut barrier integrity in lupus. Front Immunol2022; 13: 919792. doi: 10.3389/fimmu.2022.919792
29.
SilvermanGJDengJAzzouzDF. Sex-dependent lupus blautia (Ruminococcus) gnavus strain induction of zonulin-mediated intestinal permeability and autoimmunity. Front Immunol2022; 13.
MaYGuoRSunY, et al.Lupus gut microbiota transplants cause autoimmunity and inflammation. Clin Immunol2021; 233: 108892.
33.
GreilingTMDehnerCChenX, et al.Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus. Sci Transl Med2018; 10(434): eaan2306.
34.
MaYXuXLiM, et al.Gut microbiota promote the inflammatory response in the pathogenesis of systemic lupus erythematosus. Mol Med2019; 25(1): 35.
35.
WangSJKaoCHChenDU, et al.Intestinal permeability test in systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi Chin Med J Free China Ed1992; 49(1): 29–33.
36.
MuQZhangHLiaoX, et al.Control of lupus nephritis by changes of gut microbiota. Microbiome2017; 5(1): 73.
37.
OgunrindeEZhouZLuoZ, et al.A link between plasma microbial translocation, microbiome, and autoantibody development in first‐degree relatives of systemic lupus erythematosus patients. Arthritis Rheumatol2019; 71(11): 1858–1868.
38.
MuQKirbyJReillyCM, et al.Leaky gut as a danger signal for autoimmune diseases. Front Immunol2017; 8: 598.
39.
ShirakashiMMaruyaMHirotaK, et al.Effect of impaired T cell receptor signaling on the gut microbiota in a mouse model of systemic autoimmunity. Arthritis Rheumatol2022; 74(4): 641–653.
40.
LópezPde PazBRodríguez-CarrioJ, et al.Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients. Sci Rep2016; 6(1): 24072.
41.
ShinMSLeeNKangI. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol2011; 23(5): 444–448.
42.
BedoyaSKLamBLauK, et al.Th17 cells in immunity and autoimmunity. Clin Dev Immunol2013; 2013: 1–16.
43.
PanQGuoFHuangY, et al.Gut microbiota dysbiosis in systemic lupus erythematosus: novel insights into mechanisms and promising therapeutic strategies. Front Immunol2021; 12: 799788.
44.
RinninellaECintoniMRaoulP, et al.Food components and dietary habits: keys for a healthy gut microbiota composition. Nutrients2019; 11(10): E2393.
45.
Rodríguez-CarrioJLópezPSánchezB, et al.Intestinal dysbiosis is associated with altered short-chain fatty acids and serum-free fatty acids in systemic lupus erythematosus. Front Immunol2017; 8: 23.
46.
HandonoKFirdausiSNPratamaMZ, et al.Vitamin A improve Th17 and Treg regulation in systemic lupus erythematosus. Clin Rheumatol2016; 35(3): 631–638.
47.
LiaoXRenJWeiCH, et al.Paradoxical effects of all-trans-retinoic acid on lupus-like disease in the MRL/lpr mouse model. PloS One2015; 10(3): e0118176.
48.
WieërsGBelkhirLEnaudR, et al.How probiotics affect the microbiota. Front Cell Infect Microbiol2019; 9: 454.
49.
GuoXYangXLiQ, et al.The microbiota in systemic lupus erythematosus: an update on the potential function of probiotics. Front Pharmacol2021; 12: 759095.
50.
ArbuckleMRMcClainMTRubertoneMV, et al.Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med2003; 349(16): 1526–1533.
51.
HuangCYiPZhuM, et al.Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: an EXPLORER trial. J Autoimmun2022; 130: 102844.
52.
WangDZhangHLiangJ, et al.A long-term follow-up study of allogeneic mesenchymal stem/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus. Stem Cell Rep2018; 10(3): 933–941.
